Open AccessLong-Term Survival of a Patient with Glioblastoma Multiforme
Author(s) -
Radwa M. Hamed,
Abdelmonem Nasreldin Abdelmonem Hamad
Publication year - 2020
Language(s) - English
DOI - 10.47363/jcrr/2020(2)108
Subject(s) - temozolomide , glioblastoma , medicine , concomitant , oncology , adjuvant , radiation therapy , overall survival , brain tumor , surgery , pathology , cancer research
Glioblastoma multiforme (GBM) remains the most aggressive brain tumor in adults despite the advances in diagnosis and treatment over the past few decades [1]. Standard treatment for patients with newly diagnosed GBM consists of maximal safe resection followed by postoperative radiation with concomitant and adjuvant temozolomide [2]. Despite that, recurrence is common and the prognosis remains poor with a median survival of 12–15 months [3].